commentary

Letter to the Patent and Trademark Office over Potential Increase in Drug Prices

In the letter, OMI expressed concern over the proposed change that could inflict additional economic hardship on patients and their families and threaten patient health.

July 9, 2018  |  by Open Markets

The U.S. Patent and Trademark Office’s (USPTO) new proposal would change the criteria for challenging patents.  Concerned that the proposed change would make it easier for branded drug companies to exclude generic drugs from the market and cause an increase in already unaffordable prescription drug prices, Open Markets Institute submitted a letter to the USPTO.

The Open Markets Institute submitted a comment to the Patent and Trademark Office regarding Docket No. PTO-P-2018-0036: Changes to the Claim Construction Standard for Interpreting Claims in Trial Proceedings Before the Patent Trial and Appeal Board.

Read the full comment here.

 

 

Join the Movement


In America today, wealth and political power are more concentrated than at any point in our country’s history.

The Open Markets Institute, formerly the Open Markets program at New America, was founded to protect liberty and democracy from these extreme -- and growing -- concentrations of private power.

Stay updated


Sign up to stay informed.